Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

This is a first-in-human (FIH), open-label, multiple-site, dose escalation study which will evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of increasing doses of BNT317 in participants with advanced solid tumors.

Participants will be assigned to one of four dose levels of BNT317. One treatment cycle contains one treatment.

Participants may receive investigational medicinal product (IMP) for up to 2 years or until they experience disease progression, unacceptable toxicities, withdrawal of consent, or investigator decision.

In the dose escalation phase, an accelerated titration design for Dose Level 1 (DL1) and a Bayesian Optimal Interval (BOIN) design for DL2 to DL4 will be used to evaluate dose limiting toxicities (DLTs) and determine the maximum tolerated dose (MTD).

Additional dosing schedules and/or intermediate dose levels may be evaluated based on the available safety, antitumor activity, PK, and pharmacodynamic (PD) data.

Eligibility Criteria:
Key Inclusion Criteria:

* Have histologically or cytologically confirmed advanced tumors, who have failed standard therapy, or for whom no standard treatment option is available, or for whom standard therapy is not appropriate.
* Have at least one measurable lesion based on RECIST 1.1. Lesions treated after prior local treatment (radiotherapy, ablation, interventional procedures, etc.) are generally not considered as target lesions. If the lesion with prior local treatment is the only targeted lesion, evidence-based radiology must be provided to demonstrate disease progression (the single bone metastasis or the single central nervous system \[CNS\] metastasis should not be considered as a measurable lesion).
* Adequate hematologic and organ function.

Key Exclusion Criteria:

* Have received any of the following therapies or drugs within the noted time intervals prior to trial treatment:

  * Any prior treatment which inhibits cluster of differentiation 39 (CD39).
  * Vaccination with live attenuated vaccine(s) within 4 weeks prior to the first dose of IMP.
  * Broad-spectrum intravenous antibiotics therapy within 2 weeks prior to the first dose of IMP.
  * Any investigational product within 4 weeks before the first dose of IMP in this trial or ongoing participation in the active treatment phase of another interventional clinical trial.
  * Systemic cytotoxic chemotherapy, immunotherapy within 4 weeks or five half-lives of the chemotherapy (whichever is shorter) prior to the first dose of IMP.
  * Radiation therapy (chest, brain or internal organs) within 4 weeks prior to the first dose of IMP.
  * Palliative radiotherapy to a single area of metastasis within 2 weeks prior to the first dose of IMP.
  * Systemic corticosteroids (at a dosage greater than 10 mg/day of prednisone or an equivalent dose of other corticosteroids) within 2 weeks prior to the first dose of IMP. Note: local, intranasal, intraocular, intra-articular or inhaled corticosteroids, short term use (≤7 days) of corticosteroids for prophylaxis (e.g., prevention of contrast agent allergy) or treatment of non-autoimmune conditions (e.g., delayed hypersensitivity reactions caused by exposure to allergens) is allowed.
* Have any of the following CNS metastases:

  * Untreated brain metastases that are symptomatic or large (e.g., greater than 2 cm).
  * Treated CNS metastases who are not neurologically stable or on steroids or anticonvulsants within 2 weeks before initiating IMP of this trial.
  * Participants with known leptomeningeal metastases.
* Have uncontrolled hypertension or poorly controlled diabetes.
* Have a history of Allogeneic hematopoietic stem cell transplantation or organ transplantation.
* Have a history of serious Grade ≥3 immune-related adverse events (irAEs) or irAEs that led to discontinuation of a prior immunotherapy. Patients with a history of Grade ≥3 irAEs that did not lead to discontinuation of a prior immunotherapy may be included at the discretion of the investigator. If required by the investigator, after consultation with the sponsor.
* Have uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently).

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.